J&J booster meeting reopens case for lowering age limit for mRNA

Having voted 19-0 in favor of a second J&J shot, FDA’s advisory committee delved into the path forward for heterologous vaccine combinations, and reopened the debate on age limits for mRNA boosters.

A presentation on NIH’s mix-and-match study after the vote Friday left many committee members enthusiastic about moving quickly to a framework that makes heterologous vaccination available, and raised the specter of confusing the public with conflicting age limits. ...